trial

Anti-Inflammatory Treatment of Schizophrenia

NCTId NCT01514682
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 50 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2017-04-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2012-06
Primary completion
2017-04-17
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Anti-inflammatory Combination Therapy

Sponsors

University of Maryland, Baltimore CountyLead Sponsor

Investigators

2
Robert W Buchanan, MDPrincipal Investigator
William T Carpenter, MDPrincipal Investigator

Sites

1 total
Baltimore, United States

Facts & assertions

4 sourced
Enrollment
50
Phase
NA
Primary Completion Date
2017-04-17
Status
COMPLETED
relationships
The graph out of here
drug
Anti-inflammatory Combination Therapy
drug
lead_sponsor
University of Maryland, Baltimore County
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert W Buchanan, MD
person
William T Carpenter, MD
person